Floatz logo

CABAZITAXEL

Refractory Chronic Myelomonocytic Leukemia

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

98 Active assets in the Refractory Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Pevonedistat
Takeda
Phase 3BB
Venetoclax
Servier Bio-Innovation LLC
Phase 2/3BB
Azacitidine
The University of Hong Kong
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Astx727
Taiho Oncology, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →